Gynecologic Oncology Reports最新文献

{"title":"The effect of isolated tumor cells on adjuvant treatment decisions for patients with endometrial cancer: A retrospective case series","authors":"Camryn Kenkel ,&nbsp;Sarah S. Lee ,&nbsp;Naaman Mehta ,&nbsp;Jude Nawlo ,&nbsp;Edward Jimenez ,&nbsp;Leslie R. Boyd","doi":"10.1016/j.gore.2025.101713","DOIUrl":"10.1016/j.gore.2025.101713","url":null,"abstract":"<div><h3>Objective</h3><div>Sentinel lymph node biopsy (SLNB) for endometrial cancer staging may identify isolated tumor cells (ITCs). Although guidelines do not classify nodes with ITCs as positive, earlier papers reported that a significant proportion of gynecologic oncologists treat ITCs as they would positive nodes. The objective of this study was to examine practice patterns and determine if the presence of ITCs in endometrial cancer affects adjuvant treatment decision-making.</div></div><div><h3>Methods</h3><div>This was a retrospective series of patients with endometrial adenocarcinoma stages I to IIIB who underwent surgical staging with SNLB from July 2016 to January 2022 at three hospitals. The primary outcome of interest was the receipt of adjuvant treatment. Chi-square, Mann-Whitney <em>U</em> test, and logistic regression were used with significance set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Of seven hundred thirty-four patients included, ITCs were identified in 41 patients (5.6 %). Deep myometrial invasion (61.0 % vs 20.5 %, p &lt; 0.001) and lymphovascular invasion (58.4 % vs 17.7 %, p &lt; 0.001) were more common in patients with ITCs than in those with negative lymph nodes. Patients with ITCs were more likely to receive adjuvant treatment (30 of 41, 73.2 % vs 289 of 693, 41.7 %, p &lt; 0.001). When controlling for age, stage, histology, grade, and lymphovascular space invasion, ITCs were not associated with an increased likelihood of adjuvant therapy receipt.</div></div><div><h3>Conclusions</h3><div>Although patients with ITCs were more likely to receive adjuvant treatment, this was accounted for by other clinical and histological factors. Clinicians were likely to make decisions based on established risk factors, and more data are needed on the role of ITCs in the landscape of molecularly based decision making.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101713"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oligometastatic granulosa cell tumor treated with stereotactic body radiation therapy with a radiographic and tumor marker response","authors":"Madeline Petty ,&nbsp;Vasanti Jhaveri ,&nbsp;Nicholas Taylor ,&nbsp;Benjamin Foster","doi":"10.1016/j.gore.2025.101708","DOIUrl":"10.1016/j.gore.2025.101708","url":null,"abstract":"<div><div>Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic gynecologic cancers. This report details the case of a 75-year-old woman with recurrent granulosa cell tumor of the left ovary. The patient was diagnosed with a peritoneal recurrence after her inhibin-B level increased to 39.7 pg/mL, and a subsequent computed tomography (CT) scan of the abdomen and pelvis revealed an enlarging left-sided soft tissue mass in the sigmoid mesentery measuring 1.2 × 1.2 cm. She underwent SBRT, delivering 37.5 Gy in 5 fractions to the soft tissue mass. A CT scan post-treatment indicated the mass had decreased to 0.8 cm and that her inhibin B level decreased to &lt; 7 pg/mL. This case highlights the effectiveness of SBRT in the management of oligometastatic ovarian cancer, achieving a marked radiographic and tumor marker response in patients with disease not amenable to surgical resection.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101708"},"PeriodicalIF":1.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer in women under age 40: A cohort study of clinicopathological characteristics and fertility-sparing surgery outcomes","authors":"Matthew Flint ,&nbsp;Francesca Yi ,&nbsp;Mona Saleh ,&nbsp;Xulei Liu ,&nbsp;Stephanie V. Blank ,&nbsp;Yuxin Liu","doi":"10.1016/j.gore.2025.101710","DOIUrl":"10.1016/j.gore.2025.101710","url":null,"abstract":"<div><h3>Objectives</h3><div>The clinical management of cervical cancer patients under age 40 presents unique challenges, requiring a balance between complete cancer resection and fertility preservation. This study aimed to report on the clinicopathological characteristics of a cohort of young patients, along with the oncologic and reproductive outcomes of those who underwent fertility-sparing surgery (FSS).</div></div><div><h3>Methods</h3><div>The pathology database at a single institution was searched for women under age 40 who were diagnosed with invasive cervical cancer between 2015 and 2022. Electronic medical charts were reviewed for demographics, tumor characteristics, clinical management, and surveillance. Statistical analysis was performed using Wilcoxon rank-sum test and chi square test.</div></div><div><h3>Results</h3><div>A total of 57 patients (median age: 34 years; range: 27–40 years) met the inclusion criteria. Cancer histology included squamous cell carcinoma (70 %), adenocarcinoma (28 %), and adenosquamous carcinoma (2 %). The FIGO stage was I (72 %), II (7 %), III (19 %), and IV (2 %). The sensitivity of cytology was 67 %, with notably low significantly for adenocarcinoma (38 %). HPV vaccination documentation was missing for 44 patients (77 %). Among the 16 patients with stage I cancer who underwent FSS, one experienced cancer recurrence (7 %), and four successfully achieved pregnancy.</div></div><div><h3>Conclusions</h3><div>Our cohort study of young cervical cancer patients highlights deficiencies in cervical cancer prevention, including limitations in cytology-based screening and inconsistent documentation of HPV vaccination. FSS offers a promising approach, with low cancer recurrence rates and encouraging pregnancy outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101710"},"PeriodicalIF":1.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience","authors":"Daniel Jia Ming Ang ,&nbsp;Ke Xin Bok ,&nbsp;Shing Lih Wong ,&nbsp;Yihan Li ,&nbsp;Adele Wong ,&nbsp;Yen Ching Yeo ,&nbsp;Junjie Wang ,&nbsp;Ieera Madan Aggarwal ,&nbsp;Jack Junjie Chan","doi":"10.1016/j.gore.2025.101709","DOIUrl":"10.1016/j.gore.2025.101709","url":null,"abstract":"<div><div>Human papillomavirus (HPV)-independent gastric-type adenocarcinoma (GAS) is a rare, aggressive, chemoresistant histological subtype of cervical cancer which occurs more commonly in patients of Asian descent. Patients with GAS tend to have poorer overall outcomes compared to HPV-associated adenocarcinomas of the cervix. The antibody-drug conjugates (ADCs) tisotumab vedotin-tftv (TV) and trastuzumab deruxtecan (T-DXd) are approved for use in previously treated metastatic cervical cancer, the latter in HER2-expressing tumors. There is paucity of data regarding the efficacy and safety of TV and T-DXd in the management of metastatic GAS. We report outcomes of four patients with metastatic GAS who were treated with these ADCs in the second-line setting in Singapore.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101709"},"PeriodicalIF":1.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extragonadal immature teratoma of the uterus","authors":"Katherine Jane C. Chua ,&nbsp;Maryam Ali ,&nbsp;Alice Barr ,&nbsp;Rebecca Brooks ,&nbsp;Nell V. Suby","doi":"10.1016/j.gore.2025.101707","DOIUrl":"10.1016/j.gore.2025.101707","url":null,"abstract":"<div><h3>Background</h3><div>With fewer than 20 cases of extragonadal teratomas since 1929, treatment guidelines remain unclear.</div></div><div><h3>Case Presentation</h3><div>A 27-year-old nulliparous female presented with vaginal bleeding and malodorous discharge. Transvaginal ultrasound and pelvic MRI revealed a 4 cm prolapsing echogenic cervical mass that was FDG avid on PET CT. Biopsy confirmed a grade 1 polypoid immature teratoma arising from either the uterus or cervix. She underwent a total laparoscopic hysterectomy, bilateral salpingectomy, omentectomy, and primary optimal tumor debulking to R0. Bilaterally ovaries appeared grossly normal and were preserved. On final pathology, the patient was staged using FIGO ovarian cancer criteria as Stage IIIA2 grade 2 immature teratoma of the uterus. The patient received three cycles of bleomycin, etoposide, and cisplatin. The patient is 11 months post-surgery and currently undergoing surveillance.</div></div><div><h3>Conclusion</h3><div>Given the rarity of uterine immature teratomas, management of this case was extrapolated from existing recommendations for immature ovarian teratomas. Unlike in prior case reports where surgical approach was via an exploratory laparotomy, our patient underwent optimal debulking via minimally invasive surgery with ovarian preservation and adjuvant chemotherapy. Given the chemosensitive nature of germ cell tumors, further fertility sparing options for extragonadal immature teratoma may be further explored.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101707"},"PeriodicalIF":1.2,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study","authors":"Johanna Kelley ,&nbsp;Meng Yao ,&nbsp;Danielle Chau ,&nbsp;Sabrina Bedell ,&nbsp;Melissa Yurch ,&nbsp;Peter G. Rose ,&nbsp;Michelle Kuznicki","doi":"10.1016/j.gore.2025.101706","DOIUrl":"10.1016/j.gore.2025.101706","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this study is to evaluate the patterns and outcomes of maintenance bevacizumab for patients with advanced or recurrent cervical cancer.</div></div><div><h3>Methods</h3><div>This is a single-institution retrospective cohort study of patients who received clinical benefit from systemic therapy with bevacizumab from 2010 to 2022. Patients were divided into two cohorts: Cohort A received maintenance bevacizumab following therapy while Cohort B did not. Univariate Cox proportional hazards regression was performed to evaluate factors associated with progression free survival (PFS) and overall survival (OS) including age, stage, histology, hysterectomy, radiation, maintenance bevacizumab, and treatment line.</div></div><div><h3>Results</h3><div>Of 53 patients, 15 patients were in Cohort A while 38 patients were in Cohort B. In Cohort A, 60 % had complete response to initial treatment, while only 34.2 % of Cohort B had complete response (p = 0.22). Of the ten (26.3 %) patients in Cohort B who developed a fistula, all had prior radiation. On univariate analysis, maintenance bevacizumab was associated with improved PFS (p = 0.002), and OS (p = 0.007), and up front treatment (rather than treatment for recurrence) and receipt of prior brachytherapy were associated with OS (p = 0.016 and p = 0.039, respectively). Median PFS with maintenance bevacizumab was 18.7 months vs 9.6 months, (HR 0.32, p = 0.002). Median OS for those receiving maintenance bevacizumab was 39.9 months vs 15.5 months, (HR 0.34, p = 0.007).</div></div><div><h3>Conclusions</h3><div>Maintenance bevacizumab was associated with significantly prolonged PFS and OS in patients with advanced or recurrent cervical cancer who tolerated bevacizumab, but toxicity may preclude the use of maintenance therapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101706"},"PeriodicalIF":1.2,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","authors":"Sergei Iugai,&nbsp;Armando Sardi,&nbsp;Teresa Diaz-Montes,&nbsp;Mary Caitlin King,&nbsp;Vladislav Kovalik,&nbsp;Luis Felipe Falla-Zuniga,&nbsp;Kseniia Uzhegova,&nbsp;Panayotis Ledakis,&nbsp;Carol Nieroda,&nbsp;Vadim Gushchin","doi":"10.1016/j.gore.2025.101705","DOIUrl":"10.1016/j.gore.2025.101705","url":null,"abstract":"<div><h3>Introduction</h3><div>Delayed adjuvant chemotherapy (AC) worsens survival in advanced ovarian cancer (OC), but data on its impact after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is limited. We aimed to assess if delayed AC negatively affects survival in OC patients treated with CRS/HIPEC.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of a single-center prospective database including FIGO stage III-IV epithelial OC patients who underwent initial CRS/HIPEC (upfront or interval) followed by AC. Patients were grouped into delayed AC (≥60 days) and no delay (&lt;60 days). Patient characteristics were compared. Logistic regression identified risk factors for delay. Kaplan-Meier method and stratified Wilcoxon test were used for survival analysis.</div></div><div><h3>Results</h3><div>Of 95 patients identified, 43 (45.3 %) were delayed, while 52 (54.7 %) had no delay. Delayed patients were significantly older (p = 0.013), had higher stage (p = 0.038) and peritoneal cancer index (PCI) (p = 0.020), more Clavien-Dindo grade III-IV complications (p = 0.002), and longer hospital stay (p = 0.003). Age ≥ 65 years (odds ratio [OR]: 5.25, p = 0.001), PCI ≥ 24 (OR: 3.89, p = 0.006), and stage IV (OR: 3.28, p = 0.017) were associated with a higher likelihood of delay. After adjusting for stage, comorbidities, complete cytoreduction (CC)-score, and CRS type, there were no significant differences in progression-free or overall (OS) survival between groups. Subgroup analysis found early chemotherapy worsened OS in CC-0 patients (p = 0.017), while CC-1 patients demonstrated a non-significant trend towards improved OS.</div></div><div><h3>Conclusion</h3><div>Older OC patients with high tumor burden are more likely to have AC delay after CRS/HIPEC. Without clear survival benefits from early AC initiation, time to chemotherapy may be based on individual patient characteristics.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101705"},"PeriodicalIF":1.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small cell carcinoma of the cervix with syndrome of inappropriate antidiuretic hormone secretion following chemotherapy: A case report and literature review","authors":"Isabelle Lauzon ,&nbsp;Lara deGuerké ,&nbsp;Suzanne Fortin ,&nbsp;Marie-Hélène Auclair ,&nbsp;Sabrina Piedimonte","doi":"10.1016/j.gore.2025.101704","DOIUrl":"10.1016/j.gore.2025.101704","url":null,"abstract":"<div><h3>Objective</h3><div>This report aims to present a rare case of severe hyponatremia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH) following chemotherapy in a patient with small cell carcinoma of the cervix (SCCC). It also reviews the existing literature on this rare phenomenon.</div></div><div><h3>Case</h3><div>A 45-year-old female with SCCC developed acute symptomatic hyponatremia (sodium level 110 mmol/L) three days following cisplatin-based chemotherapy. SIADH was diagnosed, and the patient required intubation and admission to the intensive care unit due to severe agitation and confusion. Despite initial correction of sodium levels, the patient developed recurrent hyponatremia after subsequent chemotherapy cycles that was refractive to first line agents. She required the use of Tolvaptan, a vasopressin type 2 receptor antagonist, for the management of hyponatremia.</div></div><div><h3>Conclusions</h3><div>This case highlights the rare occurrence of severe SIADH in a patient with SCCC, underscoring the complexity of managing electrolyte disturbances in the context of both paraneoplastic syndromes and chemotherapeutic side effect. The severity of our patient’s presentation calls attention to the importance of early recognition of SIADH in the differential diagnosis of oncology patients with altered mental status and confusion. Post chemotherapy sodium surveillance could lead to improved patient outcomes, as well as monitoring for signs and symptoms of hyponatremia.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101704"},"PeriodicalIF":1.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of stage IIIC low-grade serous ovarian cancer in a 13-year-old female treated with novel therapy","authors":"Ishara Handagala ,&nbsp;Jennifer Gordon ,&nbsp;Colin NewBill ,&nbsp;Charles Anderson","doi":"10.1016/j.gore.2025.101697","DOIUrl":"10.1016/j.gore.2025.101697","url":null,"abstract":"<div><div>Low-grade serous ovarian carcinoma (LGSOC) is a rare malignancy in pediatric populations, with most ovarian tumors in adolescents typically being of germ cell origin. LGSOC is a distinct subtype of serous ovarian carcinoma characterized by slow progression, frequent estrogen receptor (ER) positivity, and resistance to traditional chemotherapy. Despite its indolent nature, most patients ultimately experience disease recurrence, highlighting the need for alternative treatment approaches. This report presents the case of a 13-year-old female diagnosed with advanced-stage LGSOC following menarche. She initially presented with unintentional weight loss, constipation, and early satiety, and imaging revealed extensive pelvic disease. Given the tumor’s limited sensitivity to chemotherapy, she was treated with neoadjuvant endocrine therapy (ET) using fulvestrant, palbociclib, and leuprolide. This regimen led to substantial tumor regression and normalization of CA-125 levels. Following 15 cycles, she underwent interval debulking surgery, achieving optimal cytoreduction while preserving the uterus. She continues adjuvant therapy with no signs of disease progression. Given the long-term effects of hormonal suppression in adolescents, careful monitoring is essential. Recent studies suggest that targeted therapies, including MEK and CDK4/6 inhibitors, may improve outcomes in LGSOC. Research has shown promising response rates and reduced toxicity compared to traditional chemotherapy. This case supports the potential role of endocrine-based targeted therapy in managing pediatric LGSOC, offering a viable alternative for patients with limited treatment options. Further research is needed to optimize treatment strategies and improve survival outcomes in this rare population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101697"},"PeriodicalIF":1.2,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ganglioglioma in mature cystic teratoma of the ovary: Case report and review of the literature","authors":"Chang Zhao ,&nbsp;Weizhen Lin ,&nbsp;Mengying Hei ,&nbsp;Weimin Liu ,&nbsp;Dayang Hui ,&nbsp;Jiexia Guan","doi":"10.1016/j.gore.2025.101700","DOIUrl":"10.1016/j.gore.2025.101700","url":null,"abstract":"<div><h3>Introduction</h3><div>Ganglioglioma of the ovary is a rare neuroectodermal-type tumor, morphologically like its counterparts in the central nervous system, and only two cases have been reported before.</div></div><div><h3>Case report</h3><div>The patient, a 30-year-old woman with no prior medical history of brain tumors or neurological disorders, was found to have a cystic mass in the left ovary, accompanied by two mural nodules. Histologically, the mural nodule in the teratoma exhibited a combination of neoplastic ganglion and glial cells. Notably, the ganglion cells exhibited binucleation and focal distribution, with the occasional presence of Nissl bodies. Immunohistochemically, GFAP and Olig2 were positive in glial cells, chromogranin A (CgA), Nestin, CD34, Neu-N, and Calretinin (CR) were positive in ganglion cells. The tumor cells demonstrated a low Ki67 index, harbored a wild-type P53 expression and were negative for IDH1 and BRAF V600E. The patient underwent laparoscopic resection of the left ovary and fallopian tube and she was in good condition at 12 months follow-up.</div></div><div><h3>Conclusions</h3><div>Ganglioglioma arising in mature cystic teratoma of the ovary is an extremely rare tumor. The description of cases is crucial for making the correct diagnosis and developing an effective treatment strategy for pathologists and clinical doctors.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101700"},"PeriodicalIF":1.2,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}